Month: August 2023

CALGARY, Alberta, Aug. 03, 2023 (GLOBE NEWSWIRE) — Sylogist Ltd. (TSX:SYZ) (“Sylogist” or the “Company”), a leading public sector SaaS company, is pleased to announce that its financial statements for the second quarter of Fiscal 2023 will be released before markets open on August 10th, 2023. The Company will host a conference call at 10:30 AM Eastern Time on August 10th, 2023. Bill Wood, Sylogist’s President and Chief Executive Officer, and Sujeet Kini, Sylogist’s Chief Financial Officer, will present the Company’s recent financial results and discuss the business’ performance. They will also address questions as time allows. Investors are invited to join the call at 1-800-806-5484 (Canada/USA Toll Free) or 416-340-2217. The participant passcode is 9270740#. Callers are asked to join 5-10 minutes prior to the scheduled start time. About...

Press Release Paris, August 3rd 2023Quarterly Turnover Section HOPS HOPSCOTCH GROUPEConsolidated turnover, first-half of 2023Continued growth : +8,2% Gross Margin HOPSCOTCH Groupe (Euronext Growth FR0000065278), a communications consulting group and a major player in Digital, Public Relations, Influence and Events, today presented its turnover and gross margin, consolidated as at June 30 2023.M€ (*) Q1 Q2 1er SemestreConsolidated turnover 2023Consolidated Gross Margin 2023 51,018,3 64,623,0 115,641,3Consolidated turnover 2022Consolidated Gross Margin 2022 45,316,7 63,521,5 108,838,2Change in turnoverChange in Gross Margin + 12,5%+ 9,3% + 1,7% + 7,0 % + 6,2%+ 8,2%(*) Unaudited data        Revenues and gross margin for the first half of 2023 reached €115.6 million and €41.3 million, up by 6.2% (revenues) and 8.2% (gross margin)...

August 3, 2023 Copenhagen, Denmark; Interim Report for the First Six Months Ended June 30, 2023 HighlightsEPKINLY™ (epcoritamab-bysp) was approved by the U.S. Food and Drug Administration (U.S. FDA) as the first bispecific antibody to treat adults with relapsed or refractory diffuse large B-cell lymphoma (DLBCL) Genmab and AbbVie Inc. (AbbVie) announced positive topline results from the Phase 1/2 EPCORE™ NHL-1 trial evaluating epcoritamab in patients with relapsed/refractory follicular lymphoma (FL) Genmab revenue increased 34% compared to the first six months of 2022, to DKK 7,052 million Genmab 2023 financial guidance updated“The U.S. FDA approval of EPKINLY as the first bispecific antibody to treat adults with relapsed or refractory DLBCL was an important milestone both for Genmab and for patients in need of an innovative...

LIMERICK, Pa., Aug. 03, 2023 (GLOBE NEWSWIRE) — The Victory Bancorp, Inc. (OTCQX: VTYB), the holding company for The Victory Bank, announced unaudited results for the quarter ended June 30, 2023. Joseph W. Major, Bank Leader and Chief Executive Officer, stated, “Despite continued disruption in the banking industry and rapidly rising rates, our team’s commitment to providing quality lending and deposit options has propelled the bank forward. We are pleased with the core performance of the bank and with the bank’s ability to grow its loans 10% percent year over year while maintaining superior credit standards. The bank’s lending and credit teams are the strongest in the company’s history.” Major concluded, “Rapid changes in market rates have put pressure on the industry, but Victory is well positioned to have its loans reprice overtime...